Evidence map›Paper›PMID 27042901›Full record

ReviewContinuum (Minneapolis, Minn.)2016

Mild Cognitive Impairment.

Ronald C Petersen

4 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Continuum (Minneapolis, Minn.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 467 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
467citing papers in PubMed, 17 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03831061 nacompletednot on this map

Intervention Through Cognitive Stimulation in People Aged 65 or Older With Mild Cognitive Impairment in Primary Care

TypeinterventionalSponsorUniversidad de ZaragozaRan2011 to 2016Enrolled122ConditionsMild Cognitive Impairment, Randomized Controlled TrialArmsCognitive stimulation
NCT06207903 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Investigating Participation Behavior: An Observational Study in Mild Cognitive Impairment Clinical Trials

TypeobservationalSponsorPower Life Sciences Inc.Ran2025 to 2027Enrolled500ConditionsMild Cognitive Impairment
NCT06598163 narecruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy of a Digital Health App Five Lives MED to Improve Cognitive Function in Patients With Mild Cognitive Impairment: a Randomised Controlled Trial

TypeinterventionalSponsorSharpTxRan2025 to 2026Enrolled170ConditionsMild Cognitive ImpairmentArmsFive Lives MED
NCT06662526 phase4not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Trace Lithium Dosage for Prevention of Cognitive Declining in Patients with Mood Illnesses: a Randomized Double Blind Placebo Controlled Trial

TypeinterventionalSponsorUniversity of ChileRan2024 to 2030Enrolled250ConditionsDementia, Bipolar Disorder (BD), Depression - Major Depressive Disorder, Mild Cognitive Impairment (MCI)ArmsTrace lithium dose plus treatment as usual, Placebo pill plus treatment as usual
3 · Its place in the literature

Who cites it

467 citing papers in PubMed, 17 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. Trial
  20. Trial

407 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ronald C Petersen

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCER01AG011378 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R. · 1993 to 2017
$12.1M
NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG011378NIA NIH HHS R01 AG041581NIA NIH HHS U01 AG006786NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

purpose of reviewAs individuals age, the quality of cognitive function becomes an increasingly important topic. The concept of mild cognitive impairment (MCI) has evolved over the past 2 decades to represent a state of cognitive function between that seen in normal aging and dementia. As such, it is important for health care providers to be aware of the condition and place it in the appropriate clinical context. RECENT

findingsNumerous international population-based studies have been conducted to document the frequency of MCI, estimating its prevalence to be between 15% and 20% in persons 60 years and older, making it a common condition encountered by clinicians. The annual rate in which MCI progresses to dementia varies between 8% and 15% per year, implying that it is an important condition to identify and treat. In those MCI cases destined to develop Alzheimer disease, biomarkers are emerging to help identify etiology and predict progression. However, not all MCI is due to Alzheimer disease, and identifying subtypes is important for possible treatment and counseling. If treatable causes are identified, the person with MCI might improve. SUMMARY: MCI is an important clinical entity to identify, and while uncertainties persist, clinicians need to be aware of its diagnostic features to enable them to counsel patients. MCI remains an active area of research as numerous randomized controlled trials are being conducted to develop effective treatments.

Indexed as

Cognitive DysfunctionDisease ProgressionHumans

Identifiers

PMID27042901
PMCPMC5390929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.